Systemic Nickel Allergy Syndrome (SNAS) remains a controversial clinical construct, characterized by persistent diagnostic uncertainty and the absence of reproducible biomarkers. Available studies are predominantly limited to small case series and uncontrolled observational reports, yielding partial and inconclusive findings. Diagnostic approaches, including oral provocation tests, frequently employ nickel exposures that far exceed typical dietary intake, raising concerns regarding physiological relevance and methodological validity. Finally, scientific inquiry into this entity has largely neglected crucial aspects such as nickel bioavailability and bioaccessibility. Against this background, particularly within the Italian clinical context, SNAS has received considerable medical and public attention despite the limited and inconsistent evidence supporting its recognition as a systemic allergic condition. Reported clinical improvements following low-nickel diets are more plausibly explained by non-specific dietary modifications-such as reduced intake of fermentable carbohydrates-rather than by a targeted immunological response to nickel. In conclusion, SNAS does not fulfill the criteria required for recognition as a discrete pathological entity. Rather, it represents a unvalidated diagnostic label for non-specific symptoms shared across established functional syndromes.
Antonello Giovannetti (Fri,) studied this question.